Do analysts rate VERO or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend VERO or AEMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aethlon Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer BJDX or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend RBOT or VERO?

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, analysts clearly believe Vicarious Surgical is more favorable than Venus Concept. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate VERO or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Venus Concept (VERO) Competitors

$0.31 0.00 (0.00%)

As of 07/20/2026

Compare

VERO vs. VBIO, AEMD, BJDX, RBOT, and LYRA

Should you buy Venus Concept stock or one of its competitors? MarketBeat compares Venus Concept with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Venus Concept include Valion Bio, Inc. Common Stock (VBIO), Aethlon Medical (AEMD), Bluejay Diagnostics (BJDX), Vicarious Surgical (RBOT), and Lyra Therapeutics (LYRA). These companies are all part of the "medical equipment" industry.

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Venus Concept (NASDAQ:VERO) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than Venus Concept. Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$6.68	N/A

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Valion Bio, Inc. Common Stock's return on equity of -138.10% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Valion Bio, Inc. Common Stock and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Valion Bio, Inc. Common Stock	Neutral

Summary

Valion Bio, Inc. Common Stock beats Venus Concept on 8 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Aethlon Medical?

Venus Concept (NASDAQ:VERO) and Aethlon Medical (NASDAQ:AEMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 2.0% of Aethlon Medical shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 0.7% of Aethlon Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Aethlon Medical has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Aethlon Medical has lower revenue, but higher earnings than Venus Concept. Aethlon Medical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Aethlon Medical	N/A	N/A	-$7.15M	-$14.69	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aethlon Medical	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Aethlon Medical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Aethlon Medical's return on equity of -137.73% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Aethlon Medical	N/A	-137.73%	-105.87%

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Aethlon Medical'saverage media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Aethlon Medical	Neutral

Summary

Aethlon Medical beats Venus Concept on 6 of the 11 factors compared between the two stocks.

How does Venus Concept compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Bluejay Diagnostics has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Bluejay Diagnostics' return on equity of -144.27% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Venus Concept	-92.76%	-1,904.25%	-85.22%

In the previous week, Bluejay Diagnostics had 3 more articles in the media than Venus Concept. MarketBeat recorded 3 mentions for Bluejay Diagnostics and 0 mentions for Venus Concept. Bluejay Diagnostics' average media sentiment score of 0.79 beat Venus Concept's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Bluejay Diagnostics	Positive
Venus Concept	Neutral

Bluejay Diagnostics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bluejay Diagnostics has higher earnings, but lower revenue than Venus Concept. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bluejay Diagnostics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

How does Venus Concept compare to Vicarious Surgical?

Vicarious Surgical (NYSE:RBOT) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 4,027.36%. Given Vicarious Surgical's stronger consensus rating and higher probable upside, analysts clearly believe Vicarious Surgical is more favorable than Venus Concept.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Vicarious Surgical had 2 more articles in the media than Venus Concept. MarketBeat recorded 2 mentions for Vicarious Surgical and 0 mentions for Venus Concept. Venus Concept's average media sentiment score of 0.00 beat Vicarious Surgical's score of -0.14 indicating that Venus Concept is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Venus Concept	Neutral

Venus Concept has higher revenue and earnings than Vicarious Surgical. Vicarious Surgical is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by insiders. Comparatively, 28.0% of Venus Concept shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vicarious Surgical has a net margin of 0.00% compared to Venus Concept's net margin of -92.76%. Vicarious Surgical's return on equity of -184.13% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Vicarious Surgical and Venus Concept tied by winning 7 of the 14 factors compared between the two stocks.

How does Venus Concept compare to Lyra Therapeutics?

Venus Concept (NASDAQ:VERO) and Lyra Therapeutics (NASDAQ:LYRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

Venus Concept has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

In the previous week, Venus Concept's average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Venus Concept	Neutral
Lyra Therapeutics	Neutral

Venus Concept has higher revenue and earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A

Venus Concept has a net margin of -92.76% compared to Lyra Therapeutics' net margin of -5,491.17%. Lyra Therapeutics' return on equity of -1,010.91% beat Venus Concept's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Venus Concept	-92.76%	-1,904.25%	-85.22%
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

87.4% of Venus Concept shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 28.0% of Venus Concept shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lyra Therapeutics beats Venus Concept on 7 of the 12 factors compared between the two stocks.

Get Venus Concept News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERO vs. The Competition

Export

Metric	Venus Concept	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$442K	$7.38B	$6.81B	$12.32B
Dividend Yield	N/A	1.32%	2.67%	9.67%
P/E Ratio	-0.01	49.84	26.97	24.18
Price / Sales	0.01	86.23	518.57	96.01
Price / Cash	N/A	26.15	49.71	59.37
Price / Book	0.07	6.94	10.67	6.25
Net Income	-$47M	$162.27M	$3.60B	$331.66M
7 Day Performance	N/A	-1.21%	-0.37%	-1.10%
1 Month Performance	N/A	-2.30%	1.80%	-1.29%
1 Year Performance	-87.58%	5.52%	25.50%	18.84%

Venus Concept Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERO Venus Concept	0.0978 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
VBIO Valion Bio, Inc. Common Stock	0.75 of 5 stars	$0.47 -7.6%	N/A	-91.1%	$1.63M	$780K	N/A	10	News Coverage Gap Down High Trading Volume
AEMD Aethlon Medical	0.3079 of 5 stars	$0.69 +2.4%	N/A	-95.3%	$1.59M	N/A	N/A	10
BJDX Bluejay Diagnostics	1.0828 of 5 stars	$1.25 +2.5%	N/A	-80.7%	$1.26M	N/A	N/A	9	News Coverage Analyst Upgrade Gap Down High Trading Volume
RBOT Vicarious Surgical	1.6299 of 5 stars	$0.17 +1.2%	$7.00 +4,142.4%	-98.4%	$1.18M	N/A	N/A	210	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERO) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Venus Concept (VERO) Competitors

VERO vs. VBIO, AEMD, BJDX, RBOT, and LYRA

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Summary

How does Venus Concept compare to Aethlon Medical?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Summary

How does Venus Concept compare to Vicarious Surgical?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Venus Concept (VERO) Competitors

VERO vs. VBIO, AEMD, BJDX, RBOT, and LYRA

How does Venus Concept compare to Valion Bio, Inc. Common Stock?

Do analysts rate VERO or VBIO?

Do institutionals and insiders hold more shares of VERO or VBIO?

Which has more risk & volatility, VERO or VBIO?

Which has stronger valuation & earnings, VERO or VBIO?

Is VERO or VBIO more profitable?

Does the media favor VERO or VBIO?

Summary

How does Venus Concept compare to Aethlon Medical?

Do insiders & institutionals hold more shares of VERO or AEMD?

Which has more volatility and risk, VERO or AEMD?

Which has stronger earnings and valuation, VERO or AEMD?

Do analysts recommend VERO or AEMD?

Is VERO or AEMD more profitable?

Does the media prefer VERO or AEMD?

Summary

How does Venus Concept compare to Bluejay Diagnostics?

Is BJDX or VERO more profitable?

Does the media favor BJDX or VERO?

Which has more volatility and risk, BJDX or VERO?

Do analysts prefer BJDX or VERO?

Which has higher earnings and valuation, BJDX or VERO?

Do institutionals and insiders hold more shares of BJDX or VERO?

Summary

How does Venus Concept compare to Vicarious Surgical?

Which has more risk and volatility, RBOT or VERO?

Do analysts recommend RBOT or VERO?

Does the media refer more to RBOT or VERO?

Which has better earnings & valuation, RBOT or VERO?

Do insiders & institutionals have more ownership in RBOT or VERO?

Is RBOT or VERO more profitable?

Summary

How does Venus Concept compare to Lyra Therapeutics?

Which has more risk & volatility, VERO or LYRA?

Does the media prefer VERO or LYRA?

Which has higher earnings and valuation, VERO or LYRA?

Is VERO or LYRA more profitable?

Do analysts rate VERO or LYRA?

Do insiders & institutionals hold more shares of VERO or LYRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERO vs. The Competition

Venus Concept Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools